Researchers from the University of Edinburgh and NHS Lothian have introduced a novel diagnostic approach that leverages fluorescence lifetime imaging microscopy and artificial intelligence to predict EGFR gene mutations in lung cancer with high accuracy. Published in Cancer Research, the technology addresses a critical bottleneck in oncology care by eliminating the need for conventional, resource-intensive gene sequencing. Lung cancer remains the leading cause of cancer-related mortality globally, and treatment efficacy frequently depends on identifying specific genetic alterations. Traditional detection methods require extensive laboratory processing, incur substantial costs, and consume limited biopsy material, which can delay patient care. The new FLIM-based system circumvents these limitations by capturing natural light emissions from untreated tissue samples. An AI algorithm then analyzes these optical signals to detect mutation patterns, successfully distinguishing between the two most clinically relevant EGFR variants. This non-destructive method preserves tissue integrity, allowing samples to undergo additional testing if required. Experts emphasize that as screening programs expand and detect earlier-stage cancers, diagnostic pathways face mounting pressure. This platform accelerates analysis from weeks to minutes and drastically reduces costs from thousands to hundreds of pounds, making precision oncology more accessible, particularly in resource-constrained health systems. The research builds upon previous work by the same team demonstrating FLIM capacity to differentiate non-small cell lung cancer subtypes from healthy tissue. Current efforts focus on clinical validation and integrating the workflow into standard hospital practice. Future iterations will expand the platform to target additional genetic mutations and other malignancies. Professor Ahsan Akram noted that a single fluorescence scan could simultaneously confirm cancer presence, classify its subtype, and predict treatment response, ensuring rapid alignment with targeted therapies. Dr. Qiang Wang highlighted the economic and temporal efficiency gains, positioning the technology as a transformative tool for diagnostic centers. Dr. David Dorward underscored the clinical necessity of high-throughput, tissue-preserving diagnostics as biopsy volumes rise. The initiative marks a significant advancement in computational pathology and precision medicine, with widespread implementation expected to streamline oncology workflows and improve patient outcomes.